EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Choosing the Right Biologic for the Right Patient With Severe Asthma

Simon Couillard, David J Jackson, Ian D Pavord, Michael E Wechsler

CHEST · 2025-02 · 167 (2) · 330-342

DOI: 10.1016/j.chest.2024.08.045 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CHEST, 2025-02. Verfasst von Simon Couillard und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC, Canada. Electronic address: s.couillard@usherbrooke.ca. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents, Biological Products. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds de recherche du Québec, Health Research Funds of Quebec.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this installment of the How I Do It series on severe asthma, we tackle the clinical conundrum of choosing the right biologic for the right patient with severe asthma. With six biologics now approved for use in this area comprising four different targeting strategies (anti-Ig E: omalizumab; anti-IL-5 and anti-IL-5-receptor: mepolizumab, reslizumab, and benralizumab; anti-IL-4-receptor: dupilumab; anti-thymic stromal lymphopoietin: tezepelumab), this question is increasingly complex. Recognizing that no head-to-head trial has compared biologics, we based our review on the expected effects of inhibiting different aspects of type 2 airway inflammation, supported whenever possible by clinical trial and real-world data. We use four variations of a case of severe uncontrolled asthma to develop concepts and considerations introduced in the previous installment ("Workup of Severe Asthma") and discuss pregnancy-related, biomarker-related, comorbidity-related, and corticosteroid dependency-related considerations when choosing a biologic. The related questions of deciding when, why, and how to switch from one biologic to another also are discussed. Overall, we consider that the choice of biologics should be based on the available clinical trial data for the desired efficacy outcomes, the biomarker profile of the patient, safety profiles (eg, when pregnancy is considered), and opportunities to target two comorbidities with one biologic. Using systemic and airway biomarkers (blood eosinophils and exhaled nitric oxide [Feno]) and other phenotypic characteristics, we suggest a framework to facilitate therapeutic decision-making. Post hoc studies and new comparative studies are needed urgently to test this framework and to determine whether it allows us to make other clinically useful predictions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAnti-Asthmatic AgentsBiological ProductsHumansSeverity of Illness IndexFemaleAntibodies, Monoclonal, HumanizedPregnancy

Stichwörter der Autor:innen

Fenoadherenceairwaysasthmabiologicsbiomarkerseosinophilsexacerbationsmultidisciplinary teamsevere asthmatype 2 inflammation

Substanzen

Anti-Asthmatic AgentsBiological ProductsAntibodies, Monoclonal, Humanizedmepolizumab

Autor:innen und Institutionen

  • Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, QC, Canada. Electronic address: s.couillard@usherbrooke.ca.
  • Guy's Severe Asthma Centre, Guy's and St Thomas' Hospitals, London, England; School of Immunology and Microbial Sciences, King's College, London, England.
  • Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, England.
  • National Jewish Health, Denver, CO.

Förderung

  • Fonds de recherche du Québec
  • Health Research Funds of Quebec

Zitieren

APA

Couillard, S., Jackson, D. J., Pavord, I. D., & Wechsler, M. E. (2025). Choosing the Right Biologic for the Right Patient With Severe Asthma. CHEST, 167(2), 330-342. https://doi.org/10.1016/j.chest.2024.08.045

Vancouver

Couillard S, Jackson DJ, Pavord ID, Wechsler ME. Choosing the Right Biologic for the Right Patient With Severe Asthma. CHEST. 2025;167(2):330-342. doi:10.1016/j.chest.2024.08.045

BibTeX
@article{Couillard2025,
  author = {Couillard, Simon and Jackson, David J and Pavord, Ian D and Wechsler, Michael E},
  title = {Choosing the Right Biologic for the Right Patient With Severe Asthma},
  journal = {CHEST},
  year = {2025},
  volume = {167},
  number = {2},
  pages = {330--342},
  doi = {10.1016/j.chest.2024.08.045}
}
Kostenlos starten →